Financial Data and Key Metrics Changes - For Q4 fiscal year 2026, revenue was $127.1 million, up 16% year-over-year, with growth led by Payment Solutions following the acquisition of AccessOne [14] - Adjusted EBITDA was $29.4 million, compared to $16.4 million in the same period last year, representing an Adjusted EBITDA margin of 23% [14] - Free cash flow was $28.5 million, up $19.3 million year-over-year, marking the strongest quarterly free cash flow to date [16] - Cash and cash equivalents as of January 31, 2026, were $73.8 million compared to $84.2 million at January 31, 2025 [16] Business Line Data and Key Metrics Changes - Average Healthcare Services Clients (AHSCs) reached 4,658, an increase of 138 from the prior quarter, with 80 of these contributed through the AccessOne acquisition [14] - Fourth quarter total revenue per AHSC was $27,279, up 8% year-over-year [14] Market Data and Key Metrics Changes - The healthcare industry is facing challenges including FDA guidelines, insurance coverage, patient utilization, and provider reimbursement, impacting visibility into spending commitments from pharmaceutical manufacturers [10][11] - Specific areas such as vaccines and public health have seen reduced spending, affecting revenue forecasts [25][61] Company Strategy and Development Direction - The company aims to position AccessOne for growth and scale its HCP marketing offering while continuing to integrate AI into its operations [13][12] - The emphasis is on building products that address access, affordability, and outcomes, with a focus on financial services and patient engagement [11] - The company is maintaining its Adjusted EBITDA outlook of $125 million-$135 million for fiscal year 2027 despite lowering revenue expectations, reflecting operational leverage and efficiency gains [19] Management's Comments on Operating Environment and Future Outlook - Management acknowledges a tough market environment but believes the underlying demand for Phreesia's offerings remains strong [10][11] - The company is experiencing shorter visibility into spending commitments, particularly in the Network Solutions business, but does not view this as a structural shift in demand [18] - Management is confident in the company's financial profile and ability to pursue growth opportunities while absorbing challenges [12][13] Other Important Information - The company completed a refinancing of its bridge loan, replacing it with a new five-year, $275 million senior secured revolving credit facility [17] - The company is prioritizing capital allocation to enhance long-term shareholder value, including potential share repurchases [17] Q&A Session Summary Question: Dynamics in the Network Solutions end market and guidance change - Management indicated that the visibility into client spending is fluid and not broad-based, affecting specific brands and therapeutic areas [24][25] Question: ProviderConnect's contribution to HCP marketing - Management stated that ProviderConnect is still in early stages and its impact on revenue outlook is minimal at this time [30] Question: Impact of price negotiations on pharma clients' budgeting - Management clarified that current issues are more related to specific therapeutic areas and regulatory activity rather than price negotiations [33] Question: Cost actions impacting EBITDA guidance - Management emphasized ongoing efficiency improvements and AI-driven operational enhancements as key to maintaining EBITDA guidance despite revenue reductions [36][37] Question: AI's impact on competitive landscape - Management believes AI capabilities will enhance the breadth of offerings and provide significant value to clients [55] Question: Visibility into Network Solutions revenue - Management noted that the lack of visibility primarily affects the second half of the fiscal year, with Q1 showing better-than-expected performance [86]

Financial Data and Key Metrics Changes - For Q4 fiscal year 2026, revenue was $127.1 million, up 16% year-over-year, with growth led by Payment Solutions following the acquisition of AccessOne [14] - Adjusted EBITDA was $29.4 million, compared to $16.4 million in the same period last year, representing an adjusted EBITDA margin of 23% [14] - Free cash flow was $28.5 million, up $19.3 million year-over-year, marking the strongest quarterly free cash flow to date [16] - The company achieved positive GAAP net income for the first time in its history as a publicly traded company [8] Business Line Data and Key Metrics Changes - Average Healthcare Services clients (AHSCs) reached 4,658, an increase of 138 from the prior quarter, with 80 of these contributed through the AccessOne acquisition [14] - Total revenue per AHSC was $27,279, up 8% year-over-year [14] Market Data and Key Metrics Changes - The healthcare industry is facing challenges including FDA guidelines, insurance coverage, patient utilization, and provider reimbursement [10] - There is variability in financial forecasts due to shorter visibility into spending commitments from certain pharmaceutical manufacturers in the Network Solutions business [11] Company Strategy and Development Direction - The company is focusing on growth initiatives such as provider financing and HCP marketing, with the acquisition of AccessOne being central to its strategy [9] - The launch of ProviderConnect is aimed at enhancing healthcare provider marketing, leveraging the existing PatientConnect platform [9] - The company is committed to building products that address access, affordability, and outcomes, with a focus on financial services and patient engagement [11] Management's Comments on Operating Environment and Future Outlook - Management acknowledges a tough market environment but believes the company is well-positioned to grow on its own terms [10] - The company is lowering its revenue outlook for fiscal year 2027 to a range of $510 million-$520 million, down from a prior range of $545 million-$559 million, due to reduced visibility into spending commitments [18] - Adjusted EBITDA outlook for fiscal year 2027 remains unchanged at $125 million-$135 million, reflecting operational leverage and efficiency gains [19] Other Important Information - The company completed a refinancing of its bridge loan, replacing it with a new senior secured revolving credit facility [17] - Cash and cash equivalents as of January 31, 2026, were $73.8 million, down from $84.2 million a year earlier [16] Q&A Session Summary Question: Dynamics in the Network Solutions end market and guidance change - Management indicated that the lack of visibility is not broad-based but specific to certain brands and therapeutic areas, such as vaccines and public health [24][25] Question: ProviderConnect's contribution to HCP marketing - Management stated that ProviderConnect is still in early stages and its impact on revenue outlook is minimal at this time [30] Question: Impact of price negotiations on pharma clients' budgeting - Management clarified that current issues are more related to specific therapeutic areas and regulatory activities rather than price negotiations [33] Question: Cost actions impacting EBITDA guidance - Management emphasized ongoing capital investment and efficiency improvements as key factors supporting the unchanged EBITDA outlook [36] Question: AI's role in competitive landscape - Management believes AI will enhance the breadth of offerings and improve operational efficiencies, positioning the company favorably in the market [55] Question: Visibility into Network Solutions revenue - Management noted that the recent updates pertain primarily to PatientConnect, with positive developments in ProviderConnect [65] Question: GLP-1 drugs impact on Network Solutions - Management categorized GLP-1 drugs as part of the challenges affecting revenue forecasts, similar to vaccines and public health issues [62] Question: Strategy for scaling AccessOne - Management indicated that growth will involve both expanding within existing competencies and exploring new opportunities in the healthcare provider ecosystem [72]

Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $32.2 million, with full-year revenue totaling $109.4 million, reflecting strong performance [3][14] - Adjusted EBITDA for Q4 2025 was $12 million, and for the full year, it was $24.3 million, indicating more than doubled year-over-year growth [3][16] - Gross margin increased from 68.1% in Q4 2024 to 74.8% in Q4 2025, attributed to a favorable product mix and channel partner strategy [14][15] - Net income for Q4 2025 was $5 million, or $0.26 per diluted share, compared to a net loss of $0.1 million in Q4 2024 [16] Business Line Data and Key Metrics Changes - The company saw solid performance across both established clients and a growing number of mid-tier and long-tail life science companies, which are viewed as attractive for future growth [3][4] - Average revenue per top 20 pharmaceutical manufacturer declined slightly from $3 million in 2024 to $2.8 million in 2025, primarily due to lower buy-ups [18] Market Data and Key Metrics Changes - The company is experiencing a broader pause in spending across its client base, with clients adopting a more conservative approach due to market shifts and negotiations related to Most-Favored-Nation pricing [4][22] - The net revenue retention rate remained strong at 116%, indicating effective customer retention despite market challenges [18] Company Strategy and Development Direction - The company is focused on transitioning more customers to a subscription-based model to enhance revenue predictability and establish a consistent recurring revenue stream [89] - A $10 million share repurchase program has been authorized, reflecting confidence in the long-term value of the business [7] - The company aims to leverage AI as a tool for efficiency, enhancing marketing execution rather than being disrupted by it [8][29] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence that current market softness is temporary and expects normalization in client spending in the coming months [5][22] - The guidance for 2026 has been updated to reflect a more conservative revenue outlook, with expected revenue between $109 million and $114 million [5][18] - Management believes there is significant opportunity for value creation, particularly in the mid-tier and long-tail segments of the market [5][46] Other Important Information - The company ended 2025 with cash and short-term investments totaling $23.4 million, up from $13.4 million in 2024, despite paying down $8 million in principal [17] - The company is uniquely positioned with a comprehensive commercialization platform that integrates advanced patient-finding capabilities [11][12] Q&A Session Summary Question: Are you seeing conservatism across all clients or just those in MFN negotiations? - Management noted a broader pause across all clients as they digest the implications of MFN negotiations, leading to shorter contract durations [22] Question: Are there nuances between DTC and HCP marketing pressures? - Management indicated that both DTC and HCP marketing are experiencing similar pressures from clients [23] Question: What drove the high gross margins in Q4, and why might they not be sustainable? - Management explained that a favorable mix of channel partners contributed to high margins, but they expect margins to normalize to the mid-60% range in 2026 [25][26] Question: How is AI impacting operations? - Management sees AI as an enabler for efficiency, allowing clients to reallocate spending from content creation to commercial execution [29][75] Question: What is the current percentage of revenue under contract? - Management indicated they are running approximately 15%-20% behind last year's contracted revenue due to shorter contract durations [35][36] Question: How does the guidance for 2026 account for managed services? - The guidance includes very little from managed services, which is considered an episodic solution [40] Question: What strategies are in place to capture mid-tier and smaller manufacturers? - The company is positioned to fill gaps for mid-tier clients lacking extensive marketing resources, leading to faster-than-expected growth in this segment [45][46]

Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $32.2 million, with full-year revenue totaling $109.4 million, reflecting strong performance [3][14] - Adjusted EBITDA for Q4 2025 was $12 million, and for the full year, it was $24.3 million, more than doubling year-over-year [3][16] - Gross margin increased from 68.1% in Q4 2024 to 74.8% in Q4 2025, attributed to a favorable product mix and channel partner strategy [14][15] - Net income for Q4 2025 was $5 million, or $0.26 per diluted share, compared to a net loss of $0.1 million in Q4 2024 [16] Business Line Data and Key Metrics Changes - The company saw solid performance across both established clients and a growing number of mid-tier and long-tail life science companies, which are viewed as attractive for future growth [3][4] - Average revenue per top 20 pharmaceutical manufacturer declined slightly from $3 million in 2024 to $2.8 million in 2025, primarily due to lower buy-ups [18] Market Data and Key Metrics Changes - The company is experiencing a broader pause in spending across its client base, particularly among those involved in Most-Favored-Nation negotiations [4][22] - The net revenue retention rate remains strong at 116%, indicating effective customer retention despite market challenges [18] Company Strategy and Development Direction - The company is focused on transitioning more customers to a subscription-based model to enhance revenue predictability and establish a consistent recurring revenue component [89] - A $10 million share repurchase program has been authorized, reflecting confidence in the long-term value of the business [7] - The company aims to leverage AI to enhance operational efficiency and marketing execution, positioning itself as a strategic partner rather than a commoditized software solution [8][29] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence that current market softness is temporary and expects normalization in client spending in the coming months [4][5] - The guidance for 2026 has been updated to reflect a more conservative revenue outlook, with expected revenue between $109 million and $114 million [5][18] - Management believes there is significant opportunity for value creation, particularly in the mid-tier and long-tail segments of the market [5][46] Other Important Information - The company achieved Rule of 40 performance and generated nearly $19 million in free cash flow from operations in 2025 [6][17] - The company is uniquely positioned with a comprehensive commercialization platform that integrates advanced patient-finding capabilities [11][12] Q&A Session Summary Question: Are you seeing conservatism across all clients or just those in MFN negotiations? - Management noted a broader pause across all clients as they digest the implications of MFN negotiations, leading to shorter contract durations [22] Question: Are there differences in spending pressure between DTC and HCP marketing? - Management indicated that spending pressure is consistent across both DTC and HCP marketing [23] Question: What drove the high gross margins in Q4 2025, and why are they not sustainable? - Management explained that the high margins were due to a favorable mix of channel partners and do not expect to maintain that level in 2026 [25][26] Question: How is AI impacting operations? - Management stated that AI is enhancing efficiency and allowing clients to reallocate budgets towards execution rather than content creation [28][29] Question: What is the current percentage of revenue under contract? - Management indicated that they are running approximately 15%-20% behind last year's contracted revenue numbers due to shorter contract durations [35][37] Question: How does the guidance for 2026 account for managed services? - Management clarified that the guidance includes very little from managed services, which is considered an episodic solution [40] Question: What strategies are in place to capture the mid-tier and long-tail market? - Management highlighted their ability to fill gaps for mid-tier clients lacking large marketing budgets, leading to faster-than-expected growth in that segment [45][46]

Core Insights - Wolters Kluwer Health's UpToDate solutions have been recognized as the top performers in the 2026 Best in KLAS – Software and Services report, highlighting their effectiveness in patient-driven care management and education [1] Group 1 - UpToDate Patient-Driven Care Management is ranked 1 in the KLAS report, indicating its strong performance in enabling patients to manage their own care [1] - UpToDate Patient Education also received a 1 ranking, showcasing its role in facilitating patient participation in healthcare [1] - KLAS Research independently evaluates healthcare technology and services based on provider feedback, underscoring the credibility of the rankings [1]

Group 1 - The company reaffirmed its full year forecast adjusted diluted EPS of $1.75 [1] - Medicaid results for July and August indicate a positive trend in the Health Benefits Ratio (HBR) improvement for the second half of the year [2] - The company has successfully refiled Marketplace rates in states covering 95% of its membership, with approvals expected by the end of the month [2]

Financial Data and Key Metrics Changes - Waystar reported Q1 2025 revenue of $256 million, reflecting a 14% year-over-year increase and an adjusted EBITDA of $108 million, which is a 16% increase year-over-year [8][26][29] - The adjusted EBITDA margin was 42%, aligning with the long-term target of approximately 40% [29][30] - The net leverage ratio at the end of Q1 was 2.5 times, indicating a decrease of approximately a quarter turn in the quarter [20][30] Business Line Data and Key Metrics Changes - Subscription revenue increased by 18% year-over-year and 3% sequentially, while volume-based revenue grew by 11% year-over-year, adjusted for a prior contract termination benefit [27][28] - The number of clients generating over $100,000 in trailing twelve-month revenue increased by 15% year-over-year to 1,244 [12][26] Market Data and Key Metrics Changes - Waystar serves over a million US-based providers across various care settings, indicating a broad market presence [9] - The company reported a 114% net revenue retention rate, which is above the typical range of 108% to 110% experienced over the past three years [26] Company Strategy and Development Direction - Waystar is focused on sustainable revenue growth, operational profitability, and innovation through its cloud-based software platform [8][11] - The company is pursuing a strategic software product roadmap that emphasizes scale, automation, and substantial ROI, including the launch of Altitude AI [14][70] - Waystar aims to leverage generative AI to enhance operational efficiency and reduce costs for clients, positioning itself as a leader in healthcare payments [16][89] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver strong performance despite macroeconomic volatility, citing the recession-resistant nature of its business model [9][30] - The company raised its full-year revenue guidance to a range of $1,060 million to $1,022 million, reflecting confidence in continued strong patient payment utilization [31][32] Other Important Information - Waystar's software platform is designed to help providers optimize cash flow and reduce administrative costs, which is critical in challenging economic conditions [9][10] - The company has maintained high cybersecurity standards and regularly audits its platform against industry-leading frameworks [19] Q&A Session Summary Question: Breakdown of Q1 outperformance and guidance components - Management indicated that strong patient payment utilization contributed to Q1 performance and guidance, with 98% of revenue coming from contracted solutions [35][36] Question: Drivers of net revenue retention rate - Management highlighted robust bookings from revenue cycle solutions and strong client advocacy as key factors driving the 114% net revenue retention rate [44][46] Question: Trends in utilization and seasonality - Management noted that utilization has trended above historical averages, benefiting the business model, with no changes in expectations for seasonality [50][53] Question: Impact of cybersecurity on sales cycles - Management confirmed that cybersecurity remains a critical factor in client decision-making, with strong demand for solutions that enhance cash flow [56][58] Question: RFP activity and tariff impact - Management observed strong demand for AI and automation solutions, with clients prioritizing efficiency amid economic challenges [68][70] Question: AI's impact on business model - Management believes that the trend of bringing outsourced RCM back in-house due to AI capabilities will benefit the business model and expand market opportunities [88][90] Question: M&A strategy post-leverage target achievement - Management expressed a disciplined approach to M&A, focusing on companies that align with Waystar's technology and client base [102][104]

Financial Data and Key Metrics Changes - Q4 revenue was $109.7 million, up 15% year over year [10] - Q4 adjusted EBITDA was $16.4 million, reflecting a significant increase from the previous year [10] - Q4 average healthcare services clients reached $4,341, an increase of $104 from the prior quarter and $379 from the prior year [10] - Q4 total revenue per AhSE was $25,266, up 5% year over year [10] - Q4 operating cash flow was positive at $16.3 million, up $19.3 million year over year [10] - Q4 free cash flow was positive at $9.2 million, up $20.1 million year over year [10] - Cash position improved to $84.2 million as of January 31, up $2.5 million from October 31, 2024 [11] Business Line Data and Key Metrics Changes - The Appresia platform was used in approximately 14% of patient visits across the United States, equating to around 170 million sites [9] - Strong growth was noted in network solutions, with expectations for similar market conditions in 2026 as in 2025 [18][19] Market Data and Key Metrics Changes - The company is monitoring macroeconomic factors closely, including consumer confidence and Medicaid changes, but has not seen significant impacts on business as of now [66][68] Company Strategy and Development Direction - The company aims to continue generating positive free cash flow while investing in long-term profitable revenue growth [11] - The revenue outlook for fiscal year 2026 is maintained at a range of $472 million to $482 million, with adjusted EBITDA expected between $78 million and $88 million [12] - The company is focused on leveraging AI and automation to improve productivity and drive business growth [32][34] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in maintaining growth despite potential macroeconomic challenges, emphasizing a strong operational foundation [66][70] - The company is committed to capital allocation strategies that prioritize durable and profitable growth, considering both organic and inorganic opportunities [70][72] Other Important Information - The company has not made any acquisitions in fiscal year 2025, but previous acquisitions are contributing to growth [75] - The company is excited about the rollout of new products that enhance patient engagement and medication adherence [8][49] Q&A Session Summary Question: What is the potential for gross margin expansion? - Management indicated that mix is a significant driver of gross margin, with expectations for higher growth in certain revenue lines contributing to expansion [16][18] Question: How are market conditions expected to change in 2026? - Management expects market conditions in 2026 to be similar to those in 2025 [19] Question: Can you explain the postscript engagement product? - The product operates on an impression-based model, leveraging data to remind patients about prescriptions [24][25] Question: What impact did the calendar have on revenue per AhSE? - Management noted that calendar factors, including holidays and weather, significantly impacted Q4 performance [30] Question: What progress has been made in leveraging AI? - Management reported positive real-time impacts from AI applications, particularly in forecasting and productivity improvements [34] Question: How is the company positioned in the competitive landscape? - Management noted improved close rates and a beneficial position as a market leader amidst new entrants [42] Question: What is the strategy for capital deployment in 2026? - The company will continue to prioritize capital allocation for durable growth, considering both organic and inorganic opportunities [70][72]